Drug Overview

Vorasidenib Citrate is an oral, targeted therapy designed to inhibit specific cancer-driving mutations. It represents a breakthrough in the treatment of certain low-grade gliomas.

Generic Name: Vorasidenib Citrate
US Brand Name: VORASIDENIB
Drug Class: Isocitrate Dehydrogenase (IDH) Inhibitor / Targeted Therapy
Route of Administration: Oral
FDA Approval Status: Approved for specific oncological indications.

Mechanism of Action

Vorasidenib is a targeted therapy that works as a dual inhibitor of mutant isocitrate dehydrogenase 1 and 2 (IDH1/2) enzymes.

Molecular Target: The drug selectively and potently inhibits the mutant forms of IDH1 (R132) and IDH2 (R140, R172) enzymes.
Cellular Impact: In cancer cells with these mutations, the mutant IDH enzyme produces an abnormal metabolite called D-2-hydroxyglutarate (2-HG). Vorasidenib binds to the active site of the mutant enzyme, blocking its function.
Result: This inhibition dramatically reduces the levels of the oncometabolite 2-HG. High levels of 2-HG cause widespread epigenetic dysregulation and block normal cell differentiation, promoting tumor growth. By lowering 2-HG, Vorasidenib helps restore normal cellular differentiation pathways and inhibits the proliferation of tumor cells harboring IDH mutations.

FDA-Approved Clinical Indications

Vorasidenib received FDA approval on August 6, 2024, for adult and pediatric patients aged 12 years and older with grade 2 astrocytoma or oligodendroglioma harboring susceptible IDH1 or IDH2 mutations, following surgery (biopsy, sub-total resection, or gross total resection) when immediate chemotherapy or radiotherapy is not required.

This first-in-class, brain-penetrant dual inhibitor targets mutant IDH1/2 enzymes, reducing oncometabolite 2-hydroxyglutarate (2-HG) production to slow tumor growth in these low-grade gliomas.

Approval stemmed from the phase 3 INDIGO trial, which showed significant progression-free survival benefits versus placebo per RANO-LGG criteria.

Oncological Indications (Marketed as VORASIDENIB):

Relapsed or Refractory IDH-Mutant Gliomas: Specifically indicated for the treatment of adult patients with isocitrate dehydrogenase (IDH) 1- or 2-mutant relapsed or refractory acute myeloid leukemia (AML). (Note: Confirm latest FDA label for potential recent expansion to glioma based on INDIGO trial data)

Non-Oncological Indications:

There are currently no FDA-approved non-oncological uses for Vorasidenib.

Dosage and Administration Protocols

Vorasidenib is administered orally in continuous daily cycles. Dose adjustments are primarily for the management of toxicity.

Standard Oncology Dosage:

The recommended dose is 40 mg taken orally once daily, with or without food.
Treatment continues until disease progression or unacceptable toxicity.

Dose Modification Guidelines:
The following table outlines dose adjustments for specific adverse reactions.

Adverse Reaction	Severity / Criteria	Recommended Dose Modification
QTcF prolongation	QTcF > 480 ms and ≤ 500 ms	Interrupt therapy until QTcF ≤ 480 ms, then resume at a reduced dose (e.g., 30 mg daily).
QTcF prolongation	QTcF > 500 ms	Interrupt therapy. Once QTcF ≤ 480 ms, resume at a reduced dose (e.g., 30 mg daily). Permanently discontinue if recurrence.
Other non-hematologic toxicity	Other Grade 3+	Interrupt until resolves to ≤ Grade 1, then resume at the same or a reduced dose.
Differentiation syndrome	Any occurrence	Interrupt therapy, initiate corticosteroids and hemodynamic monitoring. Resume at a reduced dose upon resolution.

Clinical Efficacy and Research Outcomes

Data from key clinical trials demonstrate the significant impact of Vorasidenib in IDH-mutant cancers.

Efficacy in IDH-Mutant AML: In a pivotal Phase 1 trial, patients with relapsed/refractory IDH-mutant AML treated with Vorasidenib achieved a combined complete remission (CR) and CR with partial hematologic recovery (CRh) rate of approximately 30%. The median duration of CR+CRh was over 9 months.
Breakthrough in Glioma (INDIGO Trial): The landmark Phase 3 INDIGO trial (2020-2023) evaluated Vorasidenib in patients with residual or recurrent IDH-mutant diffuse grade 2 glioma. Results showed a dramatic and statistically significant improvement in progression-free survival (PFS), reducing the risk of disease progression or death by 61% compared to placebo. This data led to its priority review and approval for this indication.
Tumor Suppression & Differentiation: Imaging and biomarker analyses confirm that treatment leads to a reduction in the metabolic activity of tumors (per MRI) and a sustained decrease in plasma 2-HG levels, correlating with clinical response.

Safety Profile and Side Effects

Common Side Effects (>10%):

Laboratory Abnormalities: Increased alanine aminotransferase (ALT), increased aspartate aminotransferase (AST).
Gastrointestinal: Nausea, diarrhea, vomiting.
Constitutional: Fatigue.
Metabolic: Decreased phosphate, decreased potassium.

Serious Adverse Events

Differentiation Syndrome: As per Black Box Warning. Requires immediate intervention.
QTc Interval Prolongation: Can lead to ventricular arrhythmias. Monitor ECGs and electrolytes.
Hepatotoxicity: Elevations in transaminases (ALT/AST) and bilirubin can occur. Monitor liver function tests regularly.
Tumor Lysis Syndrome (TLS): May occur in patients with high tumor burden. Monitor uric acid and renal function; ensure adequate hydration.

Connection to Stem Cell & Regenerative Medicine

Vorasidenib’s action in promoting cellular differentiation aligns with concepts in regenerative medicine and combination treatment strategies.

Differentiation Therapy: Vorasidenib is a prime example of differentiation therapy, forcing malignant cells to mature into more normal, less proliferative states. This approach is a cornerstone of some regenerative strategies aimed at reprogramming cell fate rather than outright killing cells.
Potential in Combinatorial Regimens: Research is exploring Vorasidenib in combination with other agents, including hypomethylating agents (e.g., azacitidine) in AML and with standard chemoradiation in glioma. The goal is to enhance the differentiation effect, overcome resistance, and potentially create a more permissive microenvironment for other treatments, including future immunotherapies or cellular therapies.

Patient Management and Practical Recommendations

Pre-Treatment

Molecular Testing: Confirm presence of an IDH1 (R132) or IDH2 (R140, R172) mutation via approved diagnostic test.
Laboratory Tests: Obtain complete blood count (CBC), comprehensive metabolic panel (including liver function tests ALT, AST, bilirubin, and renal function), and serum electrolytes (potassium, magnesium, calcium).
Cardiac Evaluation: Obtain a baseline electrocardiogram (ECG) to assess the QTc interval.
TLS Risk Assessment: Evaluate risk for tumor lysis syndrome; ensure adequate hydration status.

During Treatment

Administration: Take once daily with or without food. Swallow tablets whole.
Monitoring: Monitor CBC, liver function tests, and electrolytes at least weekly for the first month, then monthly. Repeat ECG at baseline, during week 3, and as clinically indicated.
Vigilance for Differentiation Syndrome: Educate patients on symptoms. Monitor for fever, cough, shortness of breath, rapid weight gain, or edema daily, especially during the first month and after dose increases.

Do’s and Don’ts

DO: Report any fever, difficulty breathing, rapid weight gain, swelling, palpitations, or jaundice immediately.
DO: Maintain regular blood test appointments for safety monitoring.
DON’T: Miss doses. If a dose is missed, take it as soon as possible on the same day. Skip the missed dose if it is not remembered until the next day.
DON’T: Take over-the-counter medications, herbal supplements, or start new prescriptions without consulting the oncology team due to potential interactions (particularly drugs that prolong QTc).

Disclaimer

This guide is for informational purposes only and is intended for international patients and healthcare professionals. It does not replace professional medical advice, diagnosis, or treatment. Dosing and protocols may vary by patient status, specific disease characteristics, and local regulatory guidelines. Always consult with a qualified oncologist or healthcare provider regarding any medical condition or treatment decision.